NTRA - Natera, Inc.
After hours:
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 48.81 |
| Open | 48.52 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1100 |
| Day's Range | 46.32 - 48.70 |
| 52 Week Range | 30.46 - 59.75 |
| Volume | |
| Avg. Volume | 1,165,717 |
| Market Cap | 5.458B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.54 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 73.79 |
Fair Value
Related Research
Business WireNatera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
AUSTIN, Texas, June 04, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection in kidney transplant patients, as well as additional presentations tha
Business WireNew Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
AUSTIN, Texas, May 30, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 – 6, 2023. Signatera and Natera’s circulating tumor DNA (ctDNA) technology will be featured across a wide variety of cancers, including colorectal (CRC), lung, bladder, e
Simply Wall St.Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?
Key Insights Natera's estimated fair value is US$87.69 based on 2 Stage Free Cash Flow to Equity Current share price of...
ReutersNatera wins $19 million US verdict from ArcherDX in cancer-detection patent case
Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc's blood-based DNA tests for detecting and monitoring cancer infringed three of its patents. The award was just over half of the $38 million Natera had requested, according to court documents.
- Reuters
Natera wins $19 mln US verdict from ArcherDX in cancer-detection patent case
Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc's blood-based DNA tests for detecting and monitoring cancer infringed three of its patents. The award was just over half of the $38 million Natera had requested, according to court documents.
Business WireJury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
AUSTIN, Texas, May 15, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement suit it filed against ArcherDX/Invitae Corp. The jury found that all accused ArcherDX/Invitae products infringe three of Natera’s patents. The jury determined that all three patents are valid and awarded both past lost profits and a past
Business WireNatera Reports First Quarter 2023 Financial Results
AUSTIN, Texas, May 09, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.
Insider MonkeyHere’s Why Natera (NTRA) Outperformed in Q1
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund underperformed the Russell 2000 Growth Index. The Health Care and Energy sectors contributed to the fund’s relative performance in the quarter, […]
Business WireNatera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
AUSTIN, Texas, May 08, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).
Business WireNatera Announces First Quarter 2023 Earnings Conference Call
AUSTIN, Texas, May 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
- Simply Wall St.
Revenues Working Against Natera, Inc.'s (NASDAQ:NTRA) Share Price
Natera, Inc.'s ( NASDAQ:NTRA ) price-to-sales (or "P/S") ratio of 6.9x might make it look like a buy right now compared...
Business WireNatera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
AUSTIN, Texas, April 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023.
Business WireNew Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here.
Business WireNatera Announces Commercial Payor Coverage for Signatera™
AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.
ZacksNatera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireNatera Reports Fourth Quarter and Full Year 2022 Financial Results
AUSTIN, Texas, February 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook.
ZacksIs a Surprise Coming for Natera (NTRA) This Earnings Season?
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Business WireNatera to Participate in Upcoming Investor Conferences
AUSTIN, Texas, February 24, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Business WireNatera Appoints Ruth E. Williams-Brinkley to its Board of Directors
AUSTIN, Texas, February 23, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors.
Business WireNatera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
AUSTIN, Texas, February 21, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Investor's Business DailyWhy Natera Stock Is Leading Its Industry Group With A 17% Jump Today
Natera stock broke definitively above its 200-day line Thursday after Medicare opted to reimburse for its breast cancer test.
Business WireMedicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
AUSTIN, Texas, February 16, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) that Natera’s Signatera molecular residual disease (MRD) test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer. The coverage applies across all subtypes of the di
- Simply Wall St.
Natera's (NASDAQ:NTRA) investors will be pleased with their fantastic 394% return over the last five years
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
Business WireNew Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
AUSTIN, Texas, February 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found here.
TipRanksRaymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
It’s time to take out the crystal ball and try to see what lies ahead for the stock market this year. So far, it’s clear that stocks are rebounding somewhat from the trough of 2022, and one Wall Street expert says there’s more runway for gains. Writing of the 2023 market situation, Larry Adam, chief investment officer from Raymond James, notes that last year was the second consecutive year of multiple compression – but that situation rarely repeats a third time. He’s predicting a multiple expans